Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: 35 Generic Firms To Produce Pfizer’s Paxlovid, AZ’s Evusheld Gains UK & Australian Approval

Executive Summary

Finland’s Rokote expects to begin clinical trials with its intranasal vaccine after the summer, while Australia’s ENA Respiratory has dosed the first patients in a Phase IIa study of its antiviral nasal spray.

You may also be interested in...



Coronavirus Notebook: Bivalent Spikevax OKd For Filing In Australia, Pfizer & Moderna Under Growing Pressure To Share mRNA Knowhow

The World Health Organization and UNICEF say that disruptions caused by COVID-19 and actions taken to tackle the pandemic have left many children without protection against measles and other diseases. Austria’s Apeiron has given an update on the development of its candidate therapeutic, APN01.

Global Biopharma CEOs Frustrated By IP Waiver Talk Amid COVID-19 Vaccine Glut

Top pharma executives claim ongoing vaccine inequity is not due to a lack of supply but to a shortage of sufficient infrastructure in low-and-middle income countries to administer available doses. 

MPP Announces Generic Paxlovid Licences For LMICs

A group of 35 generics manufacturers have signed agreements with the Medicines Patent Pool to supply Paxlovid generics to 95 low- and middle-income countries.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel